Till startsida

Group Jonas Nilsson

Sahlgrenska Translational Melanoma Group (SATMEG)

Research Summary

We try to identify new means to treat cancer based on our previous research on the oncogenic transcription factor c-Myc. This research has pointed on potential targets for anti-cancer drugs including kinases, epigenetic readers and metabolic enzymes.
Recently the group's activities has shifted into translating the knowledge gained from the Myc research into melanoma. Myc is overexpressed in melanoma so therefore its expression is not an optimal biomarker to define which of our previously identified targets would be viable in melanoma. Our new research therefore seek to identify biomarkers of response to new targeted therapies.
The research has generated the framework of starting the Sahlgrenska Translational Melanoma Group (SATMEG), consisting of basic researchers and clinical investigators working together to devise new therapies against melanoma. Read more about SATMEG activities here:


Current Group Members

Jonas Nilsson, PhD, Group leader at Sahlgrenska Cancer Center and Associate professor
Phone: +46 (0)31 786 6768
E-mail: jonas.a.nilsson@surgery.gu.se

Roger Olofsson, MD, PhD, Consultant surgeon
Jan Mattson, MD, PhD, Consultant surgeon

Medical Oncologists:
Lars Ny, MD, PhD, Associate professor and Consultant oncologist
Ulrika Stierner, MD, PhD, Consultant oncologist
Henrik Jespersen, MD, Resident in Oncology, PhD student

Senior Research Fellows:
Lisa Nilsson, PhD, Senior staff scientist
Lydia Green, PhD, Postdoctoral fellow

Post-graduate students:
Berglind Einarsdottir, MSc, PhD student
Joydeep Bhadury, MSc, PhD student
Somsundar Veppil Muralidharan, MSc, PhD student

Selected Publications

  1. Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types.
Fredriksson NJ, Ny L, Nilsson JA, Larsson E. 
Nat Genet. 2014

  2. Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions.
Einarsdottir BO, Bagge RO, Bhadury J, Jespersen H, Mattsson J, Nilsson LM, Truvé K, López MD, Naredi P, Nilsson O, Stierner U, Ny L, Nilsson JA. 
Oncotarget 2014:5(20):9609-18.

  3. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma.
Bhadury J, Nilsson LM, Muralidharan SV, Green LC, Li Z, Gesner EM, Hansen HC, Keller UB, McLure KG, Nilsson JA. 
Proc Natl Acad Sci U.S.A. 2014:111(26):E2721-30.
  4. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.
Gad Helge, Koolmeister Tobias, Jemth Ann-Sofie, Eshtad Saeed, Jacques Sylvain A, Ström Cecilia E, Svensson Linda M, Schultz Niklas, Lundbäck Thomas, Einarsdottir Berglind Osk, Saleh Aljona, Göktürk Camilla, Baranczewski Pawel, Svensson Richard, Berntsson Ronnie P-A, Gustafsson Robert, Strömberg Kia, Sanjiv Kumar, Jacques-Cordonnier Marie-Caroline, Desroses Matthieu, Gustavsson Anna-Lena, Olofsson Roger, et al [ Nilsson JA Nr. 53 ] Helleday Thomas. 
Nature 2014:508(7495):215-21.

  5. Antioxidants accelerate lung cancer progression in mice.
Sayin Volkan I, Ibrahim Mohamed X, Larsson Erik, Nilsson Jonas A, Lindahl Per, Bergo Martin O. 
Sci Transl Med 2014:6(221):221ra15.

  6. Mouse genetics suggests cell-context dependency for Myc-regulated metabolic enzymes during tumorigenesis.
 Nilsson Lisa M, Forshell Tacha Zi Plym, Rimpi Sara, Kreutzer Christiane, Nilsson Jonas A, 
PLoS genetics 2012:8(3):e1002573.

  7. Identification of tumorigenic and therapeutically actionable mutations in transplantable mouse tumor cells by exome sequencing.
 Bhadury Joydeep, López M D, Muralidharan S V, Nilsson Lisa M, Nilsson Jonas A. 
Oncogenesis 2013:2:e44.

  8. Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells.
 Höglund Andreas, Nilsson Lisa, Muralidharan Somsundar V, Hasvold Lisa A, Merta Philip, Rudelius Martina, Nikolova Viktoriya, Keller Ulrich, Nilsson Jonas A. 
Clinical cancer research : an official journal of the American Association for Cancer Research 2011

  9. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.
 den Hollander Jürgen, Rimpi Sara, Doherty Joanne R, Rudelius Martina, Buck Andreas, Hoellein Alexander, Kremer Marcus, Graf Nikolas, Scheerer Markus, Hall Mark A, Goga Andrei, von Bubnoff Nikolas, Duyster Justus, Peschel Christian, Cleveland John L, Nilsson Jonas A, Keller Ulrich. 
Blood 2010
  10. Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine.
 Höglund Andreas, Nilsson Lisa M, Forshell Linus Plym, Maclean Kirsteen H, Nilsson Jonas A. 
Blood 2009:113(18):4281-8.
  11. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
 Hemann Michael T, Bric Anka, Teruya-Feldstein Julie, Herbst Andreas, Nilsson Jonas A, Cordon-Cardo Carlos, Cleveland John L, Tansey William P, Lowe Scott W. 
Nature 2005:436(7052):807-11.
  12. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.
 Nilsson Jonas A, Keller Ulrich B, Baudino Troy A, Yang Chunying, Norton Sara, Old Jennifer A, Nilsson Lisa M, Neale Geoffrey, Kramer Debora L, Porter Carl W, Cleveland John L. 
Cancer Cell 2005:7(5):433-44.




To the top